Lunai Bioworks Inc.
LNAI Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.28
KIRA · Stoqly’s AI analyst, in plain words
- Lunai Bioworks Inc. had $0.1M of revenue in fiscal 2026.
- Its operating margin was −16,726.7%: of every 100 in sales, about −16,727 is left after running the business.
- Lunai Bioworks Inc. lost $3.6M in fiscal 2026.
- Free cash flow was −$5.3M in fiscal 2026, −10,171.9% of revenue.
Market cap
$0.9M
P/E
—
Revenue
$0.1M
Net income
−$3.6M
Free cash flow
−$5.3M
Operating margin
−16,726.7%
Lunai Bioworks Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−6,851.0%
No. It lost money last year.
Does profit turn into cash?
−10,171.9%
No. It spent more cash than it brought in.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lunai Bioworks Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Oct 13, 2026
- Legal name
- Lunai Bioworks Inc.
- CIK
- 0001527728
Lunai Bioworks Inc. · LNAI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | −$0.1M | — | — | $0.1M |
| Revenue growth | — | −203.8% | — | — | — |
| Net interest income | $0.1M | −$0.1M | — | — | — |
| Operating margin | −95,146.9% | 30,455.7% | — | — | −16,726.7% |
| Net income | −$113M | −$39.7M | −$88.4M | −$178M | −$3.6M |
| Net margin | −92,978.2% | 31,346.1% | — | — | −6,851.0% |
| Diluted EPS | −$2.16 | −$0.71 | −$0.91 | −$86.27 | −$1.06 |
| Cash | |||||
| Cash from operations | −$15.7M | −$11.8M | −$11.0M | −$7.9M | −$5.3M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | — | $0.0M |
| Free cash flow | −$15.7M | −$11.8M | −$11.0M | — | −$5.3M |
| FCF margin | −12,899.6% | 9,324.1% | — | — | −10,171.9% |
| Share count change | 11.4% | 7.1% | 73.3% | −97.9% | 62.9% |
| Debt and strength | |||||
| Cash and short-term investments | $9.2M | $1.9M | $0.2M | $0.1M | $1.7M |
| Shareholders' equity | $72.6M | $46.5M | $132M | −$21.3M | −$9.0M |
| Current ratio | 1.5x | 0.2x | 0.1x | 0.0x | 0.1x |
| Interest coverage | −311.4x | −66.4x | −80.7x | −260.4x | −37.0x |
| Returns and quality | |||||
| Return on equity | −91.7% | −66.6% | −99.1% | −321.8% | — |
| Return on tangible equity | −186.2% | −114.0% | — | — | — |
| Piotroski F-score | — | 2 | — | — | — |
| Altman Z'' | −10.5 | −14.9 | −6.7 | −379.6 | −186.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lunai Bioworks Inc. · LNAI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.28 a share, the company is worth $0.9M.
Source: SEC EDGAR XBRL filings (CIK 0001527728). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.